Clinical trials: Myopic Choroidal Neovascularization, open to volunteers
Myopic Choroidal Neovascularisation, Anti-VEGF Treatment
The Treatment Burden of Myopic Choroidal Neovascularization
Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue.
- Conditions
- Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden
- Trial name
- mCNV burden (NCT07009574)
- Testing
- anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Policlinico Gaspare Rodolico - San Marco Catania
Retinal Diseases, Choroidal Disease
An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings
To establish a multimodal fundus image report generation model to realize an interpretable system for multiple fundus diseases, multimodal image analysis, diagnosis, and treatment decision automatic reporting based on weakly…
- Conditions
- Retinal Diseases, Choroidal Disease, Pathological Myopia, Diabetic Retinopathy
- Trial name
- NCT06918028
- Testing
- With fundus diseases, Without fundus diseases
- Where
- China
- Volunteers
- 9,999 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Myopic Choroidal Neovascularization
Deep Learning-Based OCTA Quantification and Modeling for Predicting Long-Term Anti-VEGF Efficacy in mCNV
Myopic choroidal neovascularization (mCNV) is one of the sight-threatening complications secondary to pathological myopia. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) is its first-line therapy.
- Trial name
- NCT07402629
- Testing
- No interventions beyond routine medical care
- Volunteers
- 110 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine